Markets

Amarin's Vascepa Shows Reduced Cardiovascular Events in Kidney Patients in Latest Study

A once high-flying drug might be poised to take to the skies again. Amarin (NASDAQ: AMRN) released clinical trial results Monday that showed its Vascepa heart medicine effectively reduced cardiovascular events in patients with decreased kidney function.

The late-stage trial is a component of the company's REDUCE-IT studies aimed at gauging Vascepa's effect on at-risk patient populations.

Medical professional making heart symbol with hands.

Image source: Getty Images.

"We continue to see the consistency in benefit and safety of Vascepa administration across various at-risk patient populations, including across varying degrees of renal function," the company quoted its chief scientific officer, Steven Ketchum, as saying.

That consistency was clearly in evidence during the renal patient study. "It is notable that, despite observing with REDUCE-IT patients the known increase in cardiovascular events with decreased kidney function, all patients experienced similar relative cardiovascular risk reduction benefits, resulting in overall greater absolute risk reductions in patients with compromised kidney function," Ketchum added.

Amarin suffered a major blow with Vascepa earlier this year. In March, a court ruled in favor of two drugmakers, Hikma Pharmaceuticals and Dr. Reddy's Laboratories, which Amarin had sued over their intentions to produce and market generic versions of the drug. Amarin appealed the ruling, but a federal appeals court upheld it last month.

Since the original ruling, the company's stock has not been popular -- both the company and investors had high hopes for Vascepa, which seemed very well positioned to be a blockbuster drug as long as Amarin held exclusivity.

On Monday, Amarin's shares closed 2.4% lower, a steeper decline than the 1.9% drop in the S&P 500 index on the day.

10 stocks we like better than Amarin
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Amarin wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of October 20, 2020

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AMRN RDY

Latest Markets Videos

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More